Retrieve available abstracts of 79 articles: HTML format
Single Articles
July 2025
CIVITA P, Mazzanti CM, Lessi F, Marchio C, et al Human sporadic breast carcinoma histotypes driven by the Human Betaretrovirus
homologous to Mouse Mammary Tumor Virus.
Int J Cancer. 2025;157:371-383. PubMedAbstract available
June 2025
BENDINELLI B, Danza G, Assedi M, Villanelli F, et al Circulating sex hormones and volumetric breast density: A prospective study in
women from the EPIC Florence cohort.
Int J Cancer. 2025;156:2294-2302. PubMedAbstract available
LAI X, Luan C, Zhang Z, Wessely A, et al SOX10, MITF, and microRNAs: Decoding their interplay in regulating melanoma
plasticity.
Int J Cancer. 2025 Jun 3. doi: 10.1002/ijc.35499. PubMedAbstract available
May 2025
LANGSELIUS O, Rumgay H, de Vries E, Whiteman DC, et al Global burden of cutaneous melanoma incidence attributable to ultraviolet
radiation in 2022.
Int J Cancer. 2025 May 27. doi: 10.1002/ijc.35463. PubMedAbstract available
XIE X, Chen L, Kong X, Huo Y, et al Comparative efficacy and safety of PD-1 versus PD-L1 inhibitors in breast cancer
treatment: A systematic review and meta analysis.
Int J Cancer. 2025;156:1936-1949. PubMedAbstract available
April 2025
CHELLADURAI M, Sagi-Assif O, Ben-Menachem S, Meshel T, et al A heterodimer of hemoglobin identifies theranostic targets on brain-metastasizing
melanoma cells.
Int J Cancer. 2025 Apr 26. doi: 10.1002/ijc.35458. PubMedAbstract available
STAERK MG, Kaderly Rasmussen EL, Hannibal CG, Hertzum-Larsen R, et al Histologically verified penile lichen sclerosus-Incidence in Denmark over
26 years and long-term risk of penile and non-penile cancer.
Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35454. PubMedAbstract available
PERRIER F, Ahimbisibwe A, Ghiasvand R, Rueegg CS, et al Physical activity and mortality in melanoma patients within the Norwegian Women
and Cancer study (NOWAC).
Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35430. PubMedAbstract available
SCHMIDT ME, Hiensch AE, Depenbusch J, Monninkhof EM, et al Impact of exercise on sexual health, body image, and therapy-related symptoms in
women with metastatic breast cancer: The randomized controlled PREFERABLE-EFFECT
trial.
Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35429. PubMedAbstract available
HUANG T, Wu D, Jiang L, Wu Z, et al Neuro-astrocytic network in breast cancer brain metastases: Adaptive mechanisms
and novel therapeutic targets.
Int J Cancer. 2025 Apr 1. doi: 10.1002/ijc.35421. PubMedAbstract available
March 2025
LU W, Yao L, Wang Y, Li F, et al Characterization of extrachromosomal circular DNA associated with genomic repeat
sequences in breast cancer.
Int J Cancer. 2025 Mar 26. doi: 10.1002/ijc.35423. PubMedAbstract available
VIRAZELS M, Lusque A, Brayer S, Genais M, et al TNF signature in advanced melanoma patients treated with immune checkpoint
inhibitors: Results from the MELANFalpha clinical study.
Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35416. PubMedAbstract available
JALAGUIER S, Kuehn A, Petitpas C, Dulom A, et al The transcription factor RIP140 regulates interferon gamma signaling in breast
cancer.
Int J Cancer. 2025 Mar 10. doi: 10.1002/ijc.35405. PubMedAbstract available
February 2025
SCHWERD-KLEINE P, Wurth R, Cheytan T, Michel L, et al Biopsy-derived organoids in personalised early breast cancer care: Challenges of
tumour purity and normal cell overgrowth cap their practical utility.
Int J Cancer. 2025 Feb 28. doi: 10.1002/ijc.35386. PubMedAbstract available
January 2025
NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi
sarcoma.
Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351. PubMedAbstract available
GOLANI R, Kagenaar E, Jegu J, Belot A, et al Socio-economic inequalities in second primary cancer incidence: A competing risks
analysis of women with breast cancer in England between 2000 and 2018.
Int J Cancer. 2025 Jan 24. doi: 10.1002/ijc.35320. PubMedAbstract available
ZHOU J, Qiu T, Zhang Z, Lan Y, et al Consensus statement for the diagnosis, treatment, and prognosis of kaposiform
hemangioendothelioma.
Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35344. PubMedAbstract available
ZAHWE M, Bendahhou K, Eser S, Mukherji D, et al Current and future burden of female breast cancer in the Middle East and North
Africa region using estimates from GLOBOCAN 2022.
Int J Cancer. 2025 Jan 10. doi: 10.1002/ijc.35325. PubMedAbstract available
LUND E, Busund LR, Holden L Curvilinear incidence models for parity in the entire fertility range for cancers
of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312. PubMedAbstract available
December 2024
RODRIGUEZ MS, Mahmoud YD, Vanzulli S, Giulianelli S, et al FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast
cancer related to tumor progression.
Int J Cancer. 2024 Dec 28. doi: 10.1002/ijc.35302. PubMedAbstract available
KOUVARAKI M, Zerdes I, Sifakis EG, Sarafidis M, et al Prognostic and predictive implications of sterile alpha motif and HD
domain-containing protein 1 (SAMHD1) expression in breast cancer.
Int J Cancer. 2024 Dec 27. doi: 10.1002/ijc.35319. PubMedAbstract available
THILL M, Zahn MO, Welt A, Nusch A, et al Head-to-head comparison of palbociclib and ribociclib in first-line treatment of
HR-positive/HER2-negative metastatic breast cancer with real-world data from the
OPAL registry.
Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35296. PubMedAbstract available
MOUHANNA P, Stahlberg A, Andersson D, Albu-Kareem A, et al Integration of personalised ultrasensitive ctDNA monitoring of patients with
metastatic breast cancer to reduce imaging requirements.
Int J Cancer. 2024 Dec 18. doi: 10.1002/ijc.35292. PubMedAbstract available
CHENG TC, Huang BM, Liao YC, Chang HS, et al Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of
trastuzumab in FGFR4-overexpressing breast cancer cells.
Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35271. PubMedAbstract available
CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al Extensive epigenomic dysregulation is a hallmark of homologous recombination
deficiency in triple-negative breast cancer.
Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35274. PubMedAbstract available
November 2024
HOANG T, Lee J, Jung SY, Kim J, et al Determining risk-adapted starting age and interval for breast cancer screening
based on reproductive and hormonal factors.
Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35265. PubMedAbstract available
JIANG C, Freedman RA, Punglia RS, Jemal A, et al Associations of radiotherapy receipt with lung cancer risk by histological
subtype among breast cancer survivors in the United States.
Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257. PubMedAbstract available
LI T, Zhang M, Zhang T, Li S, et al Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A
pharmacovigilance study based on the FAERS database.
Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35255. PubMedAbstract available
CAO L, Ou D, Qi WX, Xu C, et al A randomized trial of early cardiotoxicity in breast cancer patients receiving
postoperative IMRT with or without serial cardiac dose constraints.
Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35245. PubMedAbstract available
SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for
improved recognition: A single-center study.
Int J Cancer. 2024;155:1567-1576. PubMedAbstract available
October 2024
HOLDER EX, Bigham Z, Nelson KP, Barnard ME, et al Mammographic density and breast cancer risk among Black American women.
Int J Cancer. 2024 Oct 19. doi: 10.1002/ijc.35223. PubMedAbstract available
ARIBAL E, Seker ME, Guldogan N, Yilmaz E, et al Value of automated breast ultrasound in screening: Standalone and as a
supplemental to digital breast tomosynthesis.
Int J Cancer. 2024;155:1466-1475. PubMedAbstract available
ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al Comparative sequencing study of mismatch repair and homology-directed repair
genes in endometrial cancer and breast cancer patients from Kazakhstan.
Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215. PubMedAbstract available
HAMAD W, Michell MJ, Myles JP, Gilbert FJ, et al Diagnostic performance of tomosynthesis plus synthetic mammography versus
full-field digital mammography with or without tomosynthesis in breast cancer
screening: A systematic review and meta-analysis.
Int J Cancer. 2024 Oct 12. doi: 10.1002/ijc.35217. PubMedAbstract available
QIU T, Xiang S, Zhou J, Yang M, et al Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and
resistance.
Int J Cancer. 2024 Oct 6. doi: 10.1002/ijc.35207. PubMedAbstract available
September 2024
KE C, Chen M, Lin L, Huang Y, et al Postmarketing adverse events of tamoxifen in male and female patients with breast
cancer.
Int J Cancer. 2024 Sep 21. doi: 10.1002/ijc.35193. PubMedAbstract available
PFOB A, Surovtsova I, Kokh DB, Heil J, et al Use of chemotherapy and loco-regional therapy in stage IA triple-negative breast
cancer and their association with oncologic outcomes: A cancer registry study.
Int J Cancer. 2024 Sep 18. doi: 10.1002/ijc.35189. PubMedAbstract available
BARNES I, Garcia-Closas M, Gathani T, Sweetland S, et al A comparative analysis of risk factor associations with interval and
screen-detected breast cancers: A large UK prospective study.
Int J Cancer. 2024;155:979-987. PubMedAbstract available
KOON SUN PAT M, Manraj M, Manraj S Breast cancer survival analysis in the Republic of Mauritius by age, stage at
diagnosis and molecular subtype: A retrospective cohort study.
Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35172. PubMedAbstract available
POISEUIL M, Molinie F, Dabakuyo-Yonli TS, Laville I, et al Impact of organized and opportunistic screening on excess mortality and on social
inequalities in breast cancer survival.
Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35173. PubMedAbstract available
August 2024
PERERA MM, Smit AK, Smith AL, Gallo B, et al Adherence to melanoma screening and surveillance skin check schedules tailored to
personal risk.
Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35146. PubMedAbstract available
LIU B, Song Y, Xu Y, Sun Q, et al Optimizing treatment sequence for inoperable locally advanced breast cancer:
Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a
real-world setting.
Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35140. PubMedAbstract available
KIM CE, Pereira A, Binder AM, Amarasiriwardena C, et al Time-specific impact of trace metals on breast density of adolescent girls in
Santiago, Chile.
Int J Cancer. 2024;155:627-636. PubMedAbstract available
KINDT CK, Alves CL, Ehmsen S, Kragh A, et al Genomic alterations associated with resistance and circulating tumor DNA dynamics
for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
Int J Cancer. 2024 Aug 11. doi: 10.1002/ijc.35126. PubMedAbstract available
July 2024
LEREVEREND C, Kotaich N, Cartier L, De Boni M, et al Enhanced expression of galectin-9 in triple negative breast cancer cells
following radiotherapy: Implications for targeted therapy.
Int J Cancer. 2024 Jul 30. doi: 10.1002/ijc.35107. PubMedAbstract available
FORSCHNER A, Nanz L, Maczey-Leber Y, Amaral T, et al Response and outcome of patients with melanoma skin metastases and immune
checkpoint inhibition.
Int J Cancer. 2024 Jul 20. doi: 10.1002/ijc.35103. PubMedAbstract available
KADERLY RASMUSSEN EL, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A
nationwide cohort study.
Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35101. PubMedAbstract available
GABRIELSON M, Hammarstrom M, Bergqvist J, Lang K, et al Baseline breast tissue characteristics determine the effect of tamoxifen on
mammographic density change.
Int J Cancer. 2024;155:339-351. PubMedAbstract available
TURNER JA, Van Gulick RJ, Robinson WA, Mughal T, et al Expanding the landscape of oncogenic drivers and treatment options in acral and
mucosal melanomas by targeted genomic profiling.
Int J Cancer. 2024 Jul 12. doi: 10.1002/ijc.35087. PubMedAbstract available
JIANG C, Giaquinto AN, Jemal A, Sung H, et al Trends in breast cancer incidence by estrogen receptor status in the United
States, 2004-2020.
Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35073. PubMedAbstract available
WOHLFEIL SA, Kranzmann L, Weiss C, von Wasielewski I, et al Influence of adjuvant therapies on organ-specific recurrence of cutaneous
melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry
ADOReg.
Int J Cancer. 2024 Jul 8. doi: 10.1002/ijc.35078. PubMedAbstract available
BHIMANI J, O'Connell K, Persaud S, Blinder V, et al Patient characteristics associated with delayed time to adjuvant chemotherapy
among women treated for stage I-IIIA breast cancer.
Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35053. PubMedAbstract available
June 2024
BLOEM M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, et al Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
Int J Cancer. 2024 Jun 24. doi: 10.1002/ijc.35060. PubMedAbstract available
FODA BM, Misek SA, Gallo KA, Neubig RR, et al Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant
melanoma to PD1/PDL1 blockade.
Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35056. PubMedAbstract available
KAMEI M, Matsuo K, Yoshida Y, Shimada K, et al Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL
responses through recruitment of CXCL9-expressing conventional type-1 dendritic
cells.
Int J Cancer. 2024;154:2176-2188. PubMedAbstract available
ANDREOU M, Jakalski M, Duzowska K, Filipowicz N, et al Prelude to malignancy: A gene expression signature in normal mammary gland from
breast cancer patients suggests pre-tumorous alterations and is associated with
adverse outcomes.
Int J Cancer. 2024 Jun 8. doi: 10.1002/ijc.35050. PubMedAbstract available
May 2024
DE JONGE C, Schipper RJ, Walstra CJEF, Van Riet YE, et al Breast conserving surgery with intraoperative electron beam radiation therapy for
low-risk breast cancer: Five-year follow-up of 306 patients.
Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35033. PubMedAbstract available
HAN X, Liu Y, Zhang S, Li L, et al Improving the diagnosis of ductal carcinoma in situ with microinvasion without
immunohistochemistry: An innovative method with H&E-stained and multiphoton
microscopy images.
Int J Cancer. 2024;154:1802-1813. PubMedAbstract available
HWANG HW, Shin HT, An HY, Byun JW, et al Genomic progression for local invasion of cutaneous squamous cell carcinoma from
the superficial to the deep portion.
Int J Cancer. 2024 May 13. doi: 10.1002/ijc.34952. PubMedAbstract available
BAO Y, Sui X, Wang X, Qu N, et al Extrachromosomal circular DNA landscape of breast cancer with lymph node
metastasis.
Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985. PubMedAbstract available
April 2024
BRANDT C, Vo JB, Gierach GL, Cheng I, et al Second primary cancer risks according to race and ethnicity among U.S. breast
cancer survivors.
Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971. PubMedAbstract available
KNUUTILA JS, Riihila P, Nissinen L, Heiskanen L, et al Cancer-associated fibroblast activation predicts progression, metastasis, and
prognosis of cutaneous squamous cell carcinoma.
Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34957. PubMedAbstract available
BUDUKH A, Dora T, Sancheti S, Singh V, et al Outcome of early detection approach in control of breast, cervical, and oral
cancer: Experience from a rural cancer center in India.
Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966. PubMedAbstract available
FROHLICH LM, Villar-Miyar A, Heintze T, Sauer B, et al PARP1 expression predicts PARP inhibitor sensitivity and correlates with
metastatic potential and overall survival in melanoma.
Int J Cancer. 2024 Apr 15. doi: 10.1002/ijc.34947. PubMedAbstract available
LIN YY, Gao HF, Li H, Hu Q, et al Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced
unresectable or metastatic breast cancer.
Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945. PubMedAbstract available
WANG Y, Cai W, He P, Cai Q, et al Clinical outcomes of coronavirus disease in patients with breast cancer treated
with granulocyte colony-stimulating factor following chemotherapy: Triangulation
of evidence using population-based cohort and Mendelian randomization analyses.
Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914. PubMedAbstract available
March 2024
WU H, Wang W, Zhang Y, Chen Y, et al Establishment of patient-derived organoids for guiding personalized therapies in
breast cancer patients.
Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931. PubMedAbstract available
SONGISO M, Nunez O, Cabanes A, Mutale M, et al Three-year survival of breast cancer patients attending a one-stop breast care
clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920. PubMedAbstract available
DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al Cure indicators and prevalence by stage at diagnosis for breast and colorectal
cancer patients: A population-based study in Italy.
Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923. PubMedAbstract available
BAANDRUP L, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased
risk of vulvar squamous precancer and squamous cell carcinoma.
Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34927. PubMedAbstract available
WANG T, Chai B, Chen WY, Holmes MD, et al Metformin and other anti-diabetic medication use and breast cancer incidence in
the Nurses' Health Studies.
Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917. PubMedAbstract available
KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al Health utility values of breast cancer treatments and the impact of varying
quality of life assumptions on cost-effectiveness.
Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899. PubMedAbstract available
LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al Efficacy and safety of everolimus plus exemestane in patients with hormone
receptor-positive, HER-2-negative advanced breast cancer: Results from the
open-label, multicentre, non-interventional BRAWO study.
Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912. PubMedAbstract available
LIU X, Xie X, Sui C, Liu X, et al Unraveling the cross-talk between N6-methyladenosine modification and non-coding
RNAs in breast cancer: Mechanisms and clinical implications.
Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900. PubMedAbstract available
February 2024
TANG T, Yu H, Xu S, Zhong Y, et al Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876. PubMedAbstract available
SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al Age-related phenotypes in breast cancer: A population-based study.
Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863. PubMedAbstract available
January 2024
RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al SAA1-dependent reprogramming of adipocytes by tumor cells is associated with
triple negative breast cancer aggressiveness.
Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859. PubMedAbstract available
SHARMA MP, Shukla S, Misra G Recent advances in breast cancer cell line research.
Int J Cancer. 2024 Jan 17. doi: 10.1002/ijc.34849. PubMedAbstract available
CHEN H, Yang G, Ma J Ocular toxicity associated with anti-HER2 agents in breast cancer: A
pharmacovigilance analysis using the FAERS database.
Int J Cancer. 2024 Jan 12. doi: 10.1002/ijc.34848. PubMedAbstract available